UNITED STATES
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT  
 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported)                  July 30, 2010

Angiotech Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter) 

British Columbia   000-30334   98-0226269  
(State or other jurisdiction of  (Commission  (IRS Employer 
incorporation or organization)  File Number)  Identification No.) 

1618 Station Street
Vancouver, BC, Canada V6A 1B6  
(Address of principal executive offices) 

(604) 221-7676  
(Registrant's telephone number, including area code) 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 


ITEM 2.02.   RESULTS OF OPERATIONS AND FINANCIAL CONDITION.  

On July 30, 2010, Angiotech Pharmaceuticals, Inc. (“Angiotech”) issued a press release relating to its results of operations and financial condition for the quarter ended June 30, 2010. The full text of Angiotech's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01.   FINANCIAL STATEMENTS AND EXHIBITS.  

(d) Exhibits



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Angiotech Pharmaceuticals, Inc.  
    (Registrant) 
 
 
Date:  July 30, 2010  By:  /s/ Jay Dent 
      Jay Dent 
      Sr. Vice President, Finance 



INDEX TO EXHIBITS



Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.